%0 Journal Article
%T Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang
%A Wei, James Cheng-Chung
%A Kim, Tae-Hwan
%A Kishimoto, Mitsumasa
%A Ogusu, Naoki
%A Jeong, Haeyoun
%A Kobayashi, Shigeto
%A ,
%J Annals of the Rheumatic Diseases
%@ 0003-4967
%D 2021-06-25
%I BMJ
%~ DeepDyve